New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes

New information from a signifier 2b survey being presented astatine the 2026 yearly gathering of the European Association for the Study of Diabetes (EASD) successful Milan, Italy (Sept. 28–Oct. 2), amusement that, for radical surviving with obesity and benignant 2 diabetes, attraction with Eli Lilly's caller investigational medication, EloraTZP, a operation of eloralintide and tirzepatide (TZP), resulted successful value nonaccomplishment of up to 23.3% astatine the maximum dose and accompanying important improvements successful humor sweetener control.